335 related articles for article (PubMed ID: 29718788)
21. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
Williams AR; Bergeron C; Barlow DH; Ferenczy A
Int J Gynecol Pathol; 2012 Nov; 31(6):556-69. PubMed ID: 23018219
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of vilaprisan in women with uterine fibroids: data from the ASTEROID 3 randomized controlled trial.
Al-Hendy A; Zhou YF; Faustmann T; Groettrup-Wolfers E; Laapas K; Parke S; Seitz C
F S Sci; 2023 Nov; 4(4):317-326. PubMed ID: 37437885
[TBL] [Abstract][Full Text] [Related]
23. Vilaprisan, a New Selective Progesterone Receptor Modulator in Uterine Fibroid Pharmacotherapy-Will it Really be a Breakthrough?
Ciebiera M; Vitale SG; Ferrero S; Vilos GA; Barra F; Caruso S; Laganà AS; Sierant A; Cianci A; Jakiel G
Curr Pharm Des; 2020; 26(3):300-309. PubMed ID: 31985366
[TBL] [Abstract][Full Text] [Related]
24. Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study.
Bradley LD; Singh SS; Simon J; Gemzell-Danielsson K; Petersdorf K; Groettrup-Wolfers E; Ren X; Zvolanek M; Seitz C
Fertil Steril; 2019 Feb; 111(2):240-248. PubMed ID: 30527839
[TBL] [Abstract][Full Text] [Related]
25. Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate.
Rabe T; Saenger N; Ebert AD; Roemer T; Tinneberg HR; De Wilde RL; Wallwiener M
Biomed Res Int; 2018; 2018():1374821. PubMed ID: 30539001
[TBL] [Abstract][Full Text] [Related]
26. Selective progesterone receptor modulators: current applications and perspectives.
Chabbert-Buffet N; Kolanska K; Daraï E; Bouchard P
Climacteric; 2018 Aug; 21(4):375-379. PubMed ID: 29338440
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women.
Schütt B; Kaiser A; Schultze-Mosgau MH; Seitz C; Bell D; Koch M; Rohde B
Hum Reprod; 2016 Aug; 31(8):1703-12. PubMed ID: 27288475
[TBL] [Abstract][Full Text] [Related]
28. EC313-a tissue selective SPRM reduces the growth and proliferation of uterine fibroids in a human uterine fibroid tissue xenograft model.
Nair HB; Santhamma B; Dileep KV; Binkley P; Acosta K; Zhang KYJ; Schenken R; Nickisch K
Sci Rep; 2019 Nov; 9(1):17279. PubMed ID: 31754172
[TBL] [Abstract][Full Text] [Related]
29. Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids.
Szydłowska I; Marciniak A; Nawrocka-Rutkowska J; Rył A; Starczewski A
Int J Environ Res Public Health; 2020 Jan; 17(3):. PubMed ID: 32012826
[No Abstract] [Full Text] [Related]
30. Endometrial Effects of Prolonged Therapy with the Selective Progesterone Receptor Modulator Ulipristal Acetate: A Case Report.
Levy G; Elkas J; Armstrong AY; Nieman LK
J Reprod Med; 2016; 61(3-4):159-62. PubMed ID: 27172639
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic evaluation of ulipristal acetate for uterine leiomyoma treatment.
Melis GB; Piras B; Marotto MF; Orru' MM; Maricosu G; Pilloni M; Guerriero S; Angiolucci M; Lello S; Paoletti AM
Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):901-8. PubMed ID: 22681335
[TBL] [Abstract][Full Text] [Related]
32. Application of ulipristal acetate in female patients with uterine fibroids.
Grzechocinska B; Gadomska H; Zygula A; Wielgos M
Neuro Endocrinol Lett; 2014; 35(3):175-8. PubMed ID: 24977963
[TBL] [Abstract][Full Text] [Related]
33. The endometrial response to modulation of ligand-progesterone receptor pathways is reversible.
Chodankar RR; Murray A; Nicol M; Whitaker LHR; Williams ARW; Critchley HOD
Fertil Steril; 2021 Sep; 116(3):882-895. PubMed ID: 33865567
[TBL] [Abstract][Full Text] [Related]
34. With the advent of selective progesterone receptor modulators, what is the place of myoma surgery in current practice?
Donnez J; Donnez O; Dolmans MM
Fertil Steril; 2014 Sep; 102(3):640-8. PubMed ID: 25106762
[TBL] [Abstract][Full Text] [Related]
35. Ulipristal acetate prior to in vitro fertilization in a female patient affected by uterine fibroids: a case report.
Lo Monte G; Piva I; Graziano A; Engl B; Marci R
Eur Rev Med Pharmacol Sci; 2016; 20(2):202-7. PubMed ID: 26875885
[TBL] [Abstract][Full Text] [Related]
36. Selective progesterone receptor modulators.
Whitaker LH; Williams AR; Critchley HO
Curr Opin Obstet Gynecol; 2014 Aug; 26(4):237-42. PubMed ID: 24950125
[TBL] [Abstract][Full Text] [Related]
37. Selective progesterone receptor modulators: an update.
Benagiano G; Bastianelli C; Farris M; Brosens I
Expert Opin Pharmacother; 2014 Jul; 15(10):1403-15. PubMed ID: 24787486
[TBL] [Abstract][Full Text] [Related]
38. [The molecular mechanisms and morphological manifestations of leiomyoma reduction induced by selective progesterone receptor modulators].
Demura TA; Revazova ZV; Kogan EA; Adamyan LV
Arkh Patol; 2017; 79(3):19-26. PubMed ID: 28631712
[TBL] [Abstract][Full Text] [Related]
39. The use of selective progestin receptor modulators (SPRMs) and more specifically ulipristal acetate in the practice of gynaecology.
Rozenberg S; Praet J; Pazzaglia E; Gilles C; Manigart Y; Vandromme J
Aust N Z J Obstet Gynaecol; 2017 Aug; 57(4):393-399. PubMed ID: 28567743
[TBL] [Abstract][Full Text] [Related]
40. Progesterone Signaling and Uterine Fibroid Pathogenesis; Molecular Mechanisms and Potential Therapeutics.
Ali M; Ciebiera M; Vafaei S; Alkhrait S; Chen HY; Chiang YF; Huang KC; Feduniw S; Hsia SM; Al-Hendy A
Cells; 2023 Apr; 12(8):. PubMed ID: 37190026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]